Discover trends, market shifts, and competitive outlooks for the erythropoietin (epo) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Estimated Market Size of the Erythropoietin (EPO) Market In 2029?
The expansion of the erythropoietin (EPO) market has been swift in the past few years. Its expansion is projected to go from $17.29 billion in 2024 to $19.25 billion in 2025, with a compound annual growth rate (CAGR) of 11.4%. Factors such as patient education and awareness, consolidation in the pharmaceutical industry, healthcare reimbursement policies, market growth and heightened demand, alongside patent expiration and biosimilar entry can be credited for the growth experienced in the historic period.
In the upcoming years, the market size for erythropoietin (EPO) is projected to experience significant expansion. The market is set to reach $30.92 billion by 2029, with an estimated compound annual growth rate (CAGR) of 12.6%. This considerable growth during the forecast period can be linked to various factors including market competition, the impact of biosimilars, projections of disease prevalence, changes in healthcare policy and reimbursement, development of emerging markets, and concentration on clinical trials and research. Other significant trend projections for this period encompass improvements in supply chain management, global market expansion, prioritising patient enlightenment and awareness, changes in reimbursement policies, and the consolidation and mergers in the market.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3436&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Erythropoietin (EPO) Market?
The erythropoietin market is predicted to experience substantial growth in the coming years, a change largely attributed to the escalating prevalence of chronic kidney diseases. As the number of chronic kidney disease cases rises, the need for erythropoietin, a substance which aids in the creation of red blood cells to bolster immunity, also expands. For instance, the Centers for Disease Control, a US-based federal agency, estimated that around 35.5 million U.S. adults, or roughly 14% of the population, were estimated to have chronic kidney disease (CKD) by 2023. Consequently, with an increase in chronic kidney diseases comes an expanded demand for erythropoietin, directly contributing to a rise in the market revenue.
Which Primary Segments of the Erythropoietin (EPO) Market Are Driving Growth and Industry Transformations?
The erythropoietin (EPO) market covered in this report is segmented –
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Drug Class: Biologist, Biosimilar
3) By Application: Cancer, Hematology, Renal Diseases, Neurology, Other Applications
Subsegments:
1) By Epoetin-Alfa: Epoetin-Alfa, Epoetin-Alfa Biosimilars
2) By Epoetin-Beta: Epoetin-Beta, Epoetin-Beta Biosimilars
3) By Darbepoetin-Alfa: Darbepoetin-Alfa, Darbepoetin-Alfa Biosimilars
4) By Other Products: Peginesatide, Other Novel EPO Products
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=3436&type=smp
Which Regions Are Key Players in the Growth of the Erythropoietin (EPO) Market?
The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
Which Technological Trends Are Reshaping the Erythropoietin (EPO) Industry Dynamics?
Significant players in the erythropoietin sector are putting their efforts into developing oral medications as a more user-friendly substitute for conventional injection-based treatments. The objective is to enhance patient comfort and adherence to treatment plans, and offer treatment flexibility, specifically for those dealing with persistent ailments such as anemia associated with chronic kidney disease (CKD). For example, in February 2023, GlaxoSmithKline (GSK), a global pharmaceutical and biotechnology firm from the UK, introduced Jesduvroq (daprodustat) tablets. This oral treatment aids in elevating erythropoietin levels which assists in controlling anemia in CKD patients by maintaining hemoglobin levels within the desired range. The main goal of Jesduvroq is to serve as a handier replacement for injectable treatments, thereby enhancing patient comfort, adherence, and flexible treatment options for those on dialysis.
View the full report here:
https://www.thebusinessresearchcompany.com/report/erythropoietins-global-market-report
What Parameters Are Used to Define the Erythropoietin (EPO) Market?
Erythropoietin (EPO) refers to a glycoprotein hormone that naturally induces the generation of red blood cells and is produced by the kidney’s peritubular cells. Red blood cell scarcity, or anemia, is treated with it. Weakness, weariness, and shortness of breath are signs of anemia because red blood cells deliver oxygen to the tissues and organs.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3436
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
